insulin glargine + oral hypoglycemic agents

**Insulin glargine + oral hypoglycemic agents** refers to a combination therapy used in the management of type 2 diabetes mellitus. It involves the use of **insulin glargine** (a long-acting recombinant human insulin analogue) together with one or more oral hypoglycemic agents such as metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, or thiazolidinediones. **Insulin glargine** acts by mimicking basal insulin secretion throughout the day, providing a steady glucose-lowering effect. Oral agents act through various mechanisms to either enhance insulin secretion (e.g., sulfonylureas), lower hepatic glucose production (e.g., metformin), or increase insulin sensitivity. Combining insulin glargine with oral hypoglycemic agents can achieve better glycemic control, lower fasting plasma glucose, and reduce risk of microvascular complications, especially in patients inadequately controlled on oral agents alone. Compared to NPH insulin, glargine offers a flatter pharmacodynamic profile and lower risk of nocturnal hypoglycemia[1][2][3][4].

Other names

insulin glargine plus oral antidiabetic drugsinsulin glargine combination therapyinsulin glargine + OADs